Fluor Corporation has announced that it has received a letter of intent from one of the world’s leading pharmaceutical makers to provide engineering, procurement and construction management (EPCM) services for its Lebanon, Indiana, mega-project. Fluor will recognize the multi-billion-dollar reimbursable contract as a new award in the first quarter of 2025.
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 2023.
The facility will manufacture groundbreaking peptide-based drugs for Type 2 diabetes and weight control and represents the largest investment in an active pharmaceutical ingredient facility in U.S. history.
“This monumental project stands as one of the largest life science endeavors ever undertaken in a single initiative and demonstrates Fluor’s EPCM leadership position in the sector,” said Richard Meserole, President of Fluor’s Advanced Technologies & Life Sciences business. “The products this facility manufactures have the ability to enhance the overall wellbeing of its users globally. Fluor is honored to be delivering it.”
Source: Fluor Corporation